Hours after US President Donald Trump imposed broad tariffs on Canada, Mexico, and China, citing illegal immigration and drug ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...